NORTH-REG Dwell-Time Study

Nordic Urothelial Cancer Research Group Study on Reduced BCG Dwell-Time in High Risk NMIBC

Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations. This will increase their risk of recurrence and potential cystectomy. The purpose of this study is to investigate if NMIBC patients who experience severe side effects to BCG instillations will experience fewer or less severe side effects if reducing dwell-time of BCG instillations.

The study will include patients from Denmark, Iceland, Norway and Sweden.

Study Overview

• Status: Recruiting
• Conditions: Side Effect of Drug
• Intervention / Treatment: Drug: Bacillus Calmette Guerin

Detailed Description

Approximately 8,000 patients are diagnosed with bladder cancer (BC) in the Nordic countries every year. The majority of BC patients are diagnosed with non-muscle invasive bladder cancer (NMIBC). The majority of NMIBC are treated with Bacillus Calmette-Guérin vaccine (BCG) as adjuvant treatment but for carcinoma in situ it is the primary treatment. BCG is known to give a lot of side effects both local and systemic, the severity of these can lead to premature termination of the treatment.

The object of this PhD project is to investigate if reduced dwell time, the time the BCG is in the bladder, will decrease the severity of side effects due to BCG instillations.

This will be investigated in a Nordic setting and the project will be done as a two-armed randomized clinical trial.

By decreasing the severity of side effects, we hypothesize the number of patients completing all planned instillations will increase and thereby decrease the risk of the BC evolving into a more aggressive type.

• Study Type: Interventional
• Enrollment (Estimated): 314
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Jørgen B. Jensen, Professor,DMSc; Phone Number: +45 78452617; Email: Bjerggaard@skejby.rm.dk
• Study Contact Backup: Name: Lene Munk, MD

Study Locations

• Denmark
  • Aalborg, Denmark, 9100
    • Recruiting
    • Department of Urology, Aalborg University Hospital
    • Contact: Knud Fabrin, MD
  • Herlev, Denmark
    • Recruiting
    • Herlev Hospital
    • Contact: Gitte Lam, MD
  • Herning, Denmark, 7400
    • Recruiting
    • Regional hospital Gødstrup
    • Contact: Erik Hansen, MD
  • København, Denmark, 2100
    • Not yet recruiting
    • Department of Urology, Rigshospitalet
    • Contact: Ulla Nordström Joensen, MD, PhD Assoc. Professor
  • Odense, Denmark, 5000
    • Recruiting
    • Odense University Hospital
    • Contact: Lasse Bro, MD
  • Roskilde, Denmark, 4000
    • Recruiting
    • Zealand University Hospital
    • Contact: Juan Luis Vásquez, MD
  • Aarhus N
    • Aarhus, Aarhus N, Denmark, 8200
      • Recruiting
      • Aarhus University Hospital
      • Contact: Lene Munk, MD
• Iceland
  • Reykjavík, Iceland, 101
    • Recruiting
    • Landspitali University Hospital
    • Contact: Sigurdur Gudjonsson
• Sweden
  • Göteborg, Sweden, sw 413 45
    • Recruiting
    • PO Sahlgrenska Universitetssjukhuset
    • Contact: Viveka Ströck, MD
  • Stockholm, Sweden, 141-86
    • Recruiting
    • Karolinska University Hospital
    • Contact: Tomas Thiel, MD
  • Örebro, Sweden, 701 85
    • Recruiting
    • Orebro University Hospital
    • Contact: Tomas Jerlsström

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• ≥18 years of age at the time of signing the Informed Consent Form
• Signed Informed Consent Form
• Patients with NMIBC where BCG therapy including maintenance for 1 year is planned for one of the following histopathological findings:
• Ta high grade without CIS
• CIS with or without previous or concomitant Ta tumors
• T1 with or without CIS
• Is, according to the Investigator's judgement, able to comply with the trial protocol
• Ability to understand the Patient Information Sheet orally and in writing

Exclusion Criteria:

• Previous BCG instillations within the last 2 years, because of the risk of not having cleared potential previos side effects.
• T1 tumors where re-resection had not been performed
• TUR-B, bladder biopsy or traumatic catheterization within 2 weeks.
• Previous or current MIBC
• Progression defined as progrssion to T1-tumour, T2+_tumour or cystectomy irrespectievely of indication or development of metastatic urothelial cancer irrespectively of tumour stage
• Contraindications to BCG
• Incontinence
• Bilateral nephrostomy catheters; unilateral nephrostomy catheter is allowed if permanent for the duration of all inistallations with BCG and a normally functioning kidney.
• Need for catheter a demeure at the time of instillation
• Immune Suppressing medication (cancer therapy e.g cytostatic medicinal products, radiation, local and systemic steroids like e.g. prednisolone is permitted)
• Reduced immune response (leukaemia, lymphoma)
• Known allergy or sensitivity to BCG
• HIV infection
• Signs of active tuberculosis
• Any type of previosly radiation therapy involving the bladder.
• Concomitant invasive cancer within 5 years other than non-melanoma skin cancer and protate cancer without metastasis
• Current urinary tract infection
• Patient with visible hematuria
• Current alcohol and/or drug abuse
• Has a mental or legal incapacitation or another condition which impair the subject's ability to participate
• Has participated in another interventional clinical study and treatment with another investigational product 30 days prior to randomization
• For women study subjects: Pregnancy or breastfeeding
• For women Study subjects of childbearing potential: unless they are using highly effective methods of contraception from the first BCG instillations until 14 days after last dose of BCG treatment, which are defined as total abstinence, female sterilization, use of oral methods of contraception or placement of an intrauterine contraception devices.
• For male Study Subjects: unless they are using highly effective methods of contraception from the first BCG instillation until for 14 days after last dose of BCG treatment, which is defined as total abstinence or use of condoms.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention; Study Subjects randomized to the interventional arm will be assigned to BCG induction therapy once-weekly for 6 weeks and subsequent 1 year of maintenance (6+3x3) of which dwell-time during the first of the 6 induction instillations is 2 hours. If side effects are registered before the second and all further instillations, Study Subject in the intervention arm will be reduced in dwell-time according to the grading of side effects as given by the study algorithm.	Drug: Bacillus Calmette Guerin; The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.
Active Comparator: Control; The Study Subjects will be treated according to guidelines with BCG instillation therapy once weekly for 6 weeks and subsequent 1 year of maintenance therapy (6+3x3) with 2 hours of dwelltime.	Drug: Bacillus Calmette Guerin; The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Completion of instillations	Number of Study Subjects completing all 6 induction instillations and subsequent maintenance installations for 12 months (6 + 3 x 3)	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recurrence rate	Recurrence rate within 24 months in Study Subjects with initial complete response	5 years

Collaborators and Investigators

• Sponsor: Jørgen Bjerggaard Jensen
• Collaborators: Odense University Hospital; Karolinska University Hospital; Zealand University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Sahlgrenska University Hospital, Sweden; Herlev Hospital; Aalborg University Hospital; Region Örebro County; Landspitali University Hospital; Regional Hospital West Jutland

Study record dates

Study Major Dates

• Study Start (Actual): February 3, 2021
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2030

Study Registration Dates

• First Submitted: January 6, 2021
• First Submitted That Met QC Criteria: January 6, 2021
• First Posted (Actual): January 8, 2021

Study Record Updates

• Last Update Posted (Estimated): December 14, 2023
• Last Update Submitted That Met QC Criteria: December 13, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Chemically-Induced Disorders; Drug-Related Side Effects and Adverse Reactions; Physiological Effects of Drugs; Immunologic Factors; Adjuvants, Immunologic; BCG Vaccine
• Other Study ID Numbers: 2020-003112-27

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No